(20,000) (1,150)
Net Investment Loss 4,643 3,773
Branded License Fees and Premium Paid on Equity
Investments 19,150 -
Severance Costs 1,643 7,106
Net Settlements (Gain) Losses (578) 1,502
Write-off of Accounts Receivable Relating to
Invalid Customer Deductions - 9,965
Estimated Tax on Adjustments (1,895) (8,266)
Adjusted Net Income (non-GAAP measure) $48,544 $14,626
Diluted Earnings Per Share:
Reported $1.30 $0.05
Adjusted (non-GAAP measure) $1.39 $0.42
* 2006 amounts represent $3,054 gain on sale of product rights net of
$1,904 loss on the return of inventory from a customer relating to the
same agreement.
Estimated Operating Results for Full Year 2007
ESTIMATED REPORTED GAAP RESULTS FY 2007
(in millions, except per share amounts)
Total Revenue $760 - $780
SG&A $130 - $133
R&D $75 - $80
Reported GAAP EPS (fully diluted) $1.45 - $1.50
Other supplemental information
Depreciation & amortization $24 - $26
Share-based compensation $18 - $20
IMPACT OF NON-GAAP ITEMS FY 2007
(in millions, except per share amounts)
Reported GAAP EPS (fully diluted) $1.45 - $1.50
Severance $2
Branded Milestone Payments $19
High Y
'/>"/>
SOURCE Par Pharmaceutical Companies, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1.
Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business2.
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference3.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)4.
Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet5.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)6.
National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership7.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)8.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma9.
Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 200710.
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences11.
Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance